# A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

> **NCT04810078** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 681 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Nivolumab and rHuPH20
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04810078
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-21
- **Primary completion:** 2025-07-29
- **Final completion:** 2027-05-10
- **Target enrollment:** 681 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04810078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04810078, "A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04810078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*